eosinophilic asthma

Mepolizumab (SB 240563) is a humanized monoclonal antibody that neutralizes IL-5, and can be utilized in research on severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis.

Benralizumab (MEDI-563) is a monoclonal antibody targeting the interleukin-5 receptor alpha (IL-5Rα). It enhances antibody-dependent cell-mediated cytotoxicity, leading to a rapid depletion of eosinophils. Benralizumab is used for severe eosinophilic asthma and can be employed to prevent exacerbations of chronic obstructive pulmonary disease.

SHR-1703 is a long-acting humanized anti-IL-5 IgG1 monoclonal antibody. It selectively identifies and binds to IL-5, preventing IL-5 from associating with the α chain of eosinophil surface receptors. This action inhibits the proliferation, activation, and migration of eosinophils, ultimately reducing eosinophil-mediated inflammation and damage. SHR-1703 is applicable for research into eosinophil-related diseases, such as eosinophilic asthma. The recommended isotype control is HumanIgG1kappa, Isotype Control.